How Scientists Are Making Peptide Drugs Work as Pills Instead of Injections | Research

The takeaway

This review maps the strategies being used to turn injectable peptide drugs into oral pills by overcoming the barriers in your digestive system.

3 major barriers
Mucus, digestive enzymes, and the intestinal epithelium — oral peptide drugs must overcome all three to reach the bloodstream.

What the researchers found

This review catalogs the major barriers peptide and protein drugs face when taken orally — mucus, digestive enzymes, and the intestinal cell lining — and the pharmaceutical strategies being used to overcome them. Key approaches include: co-administration with protease inhibitors to prevent enzymatic breakdown, PEGylation and mucoadhesive polymers to extend gut residence time, cell-penetrating peptides to cross the intestinal barrier, nanoparticle carriers (liposomes, microspheres, nanospheres) for protected transport, and enteric coatings to survive stomach acid. The review also covers formulations that have reached clinical approval.

Why it matters

Most peptide drugs currently require injection because the digestive system destroys them before they can be absorbed. Converting injectable peptide therapies to oral pills would make them far more accessible, especially for children and patients who need daily dosing. This review maps the entire landscape of strategies being used to solve this problem, from established techniques to emerging approaches.

How the study worked

This is a narrative review paper synthesizing published research on pharmaceutical strategies for oral delivery of therapeutic peptides and proteins. The authors review the biological barriers in the GI tract, the modification strategies used to enhance oral bioavailability, and clinically approved oral peptide formulations.

Who was studied

Review covering both adult and pediatric populations (no direct study population)

What this study cannot tell us

As a review, this paper synthesizes existing knowledge but doesn't present new experimental data. The field moves quickly, so some strategies discussed may have progressed or been abandoned since publication. The pediatric perspective, while highlighted in the title, may be less extensively covered than adult applications given the smaller body of pediatric peptide research.

How to read the evidence

This is a moderate-strength review that comprehensively surveys the field of oral peptide delivery. It synthesizes evidence from numerous preclinical and clinical studies but doesn't generate new experimental data.

When this study was published

Published in 2020. The oral peptide delivery field has advanced significantly since, particularly with the commercial success of oral semaglutide and new absorption enhancer technologies.

The bigger picture

The push to make peptide drugs orally available is one of the biggest trends in pharmaceutical development. Oral semaglutide (Rybelsus) proved it's possible, and dozens of other peptide drugs are being reformulated for oral delivery. This review provides a comprehensive map of the toolbox available to drug developers, which is especially relevant as the GLP-1 agonist market drives massive investment in oral peptide formulations.

Questions still open

Which of these oral delivery strategies will prove most effective for the next generation of peptide drugs?
Can oral peptide delivery achieve bioavailability levels comparable to injection for most therapeutic peptides?
What unique challenges does pediatric oral peptide delivery present compared to adult formulations?

Common questions

Why can't most peptide drugs simply be taken as pills?

Your digestive system is designed to break down proteins and peptides from food. When you swallow a peptide drug, stomach acid, digestive enzymes, and the mucus lining of your intestines work together to destroy it or block its absorption before it can reach your bloodstream. Only about 1% or less of an oral peptide dose typically makes it through.

What are cell-penetrating peptides and how do they help?

Cell-penetrating peptides (CPPs) are short amino acid sequences that have a special ability to cross cell membranes. By attaching a CPP to a therapeutic peptide, scientists can help the drug pass through the intestinal lining and into the bloodstream — essentially giving the drug a molecular passport to cross the gut barrier.

Read the original research

An Update on Pharmaceutical Strategies for Oral Delivery of Therapeutic Peptides and Proteins in Adults and Pediatrics.

Children (Basel, Switzerland), 7(12)

View on PubMed ↗Publisher’s paper ↗

Citation

Dan, Nirnoy; Samanta, Kamalika; Almoazen, Hassan. (2020). An Update on Pharmaceutical Strategies for Oral Delivery of Therapeutic Peptides and Proteins in Adults and Pediatrics.. Children (Basel, Switzerland), 7(12). https://doi.org/10.3390/children7120307